Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news